carbinoxamine maleate (clistin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Carbinoxamine is a histamine-H1 receptor blocking agent. It is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. Carbinoxamine is effective for the symptomatic treatment of seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis due to inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Most common adverse reactions are: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. Avoid concomitant use of alcohol and CNS depressants (hypnotics sedatives, tranquilizers, etc.) due to additive adverse effects.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.3448 - $5.4415
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

{2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine | 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine | carbinoxamin | carbinoxamina | carbinoxamine | (+-)-carbinoxamine | carbinoxamine base | carbinoxamine diphenyldisulfonate | carbinoxamine maleate | carbinoxamine tannate | carbinoxaminum | cisti | clistin | davenol | histex ct | histex i-e | histex pd | n,n-dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine | palgic | paracarbinoxamine | paracarinoxamine

Organizations (14)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (7)


 

Anaphylaxis (approved 2003)

Angioedema (approved 2003)

Conjunctivitis, Allergic (approved 2003)

Rhinitis, Allergic, Perennial (approved 2003)

Rhinitis, Allergic, Seasonal (approved 2003)

Rhinitis, Vasomotor (approved 2003)

Urticaria (approved 2003)

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Common Cold (Phase 4)

Cough (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue